← Ablatotech Vitals
GeriatricMedicine EvidenceDigest

Clinical evidence and management strategies for optimizing vaccination uptake and effectiveness in older adults beyond COVID-19

GeriatricMedicine · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 20, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Optimizing vaccination uptake and effectiveness in older adults beyond COVID-19 remains a critical public health priority given their increased vulnerability to infectious diseases such as influenza, pneumococcal disease, and herpes zoster. Evidence highlights multifactorial barriers to vaccine acceptance, including hesitancy driven by misinformation and access issues, as well as immunosenescence that may reduce vaccine immunogenicity. Tailored strategies combining patient education, healthcare provider engagement, and system-level interventions can improve uptake. Additionally, emerging evidence supports the use of enhanced vaccine formulations and booster doses to augment immune responses in this population. However, ongoing surveillance and individualized approaches are needed to balance benefits and risks, especially in frail or multimorbid older adults.

Clinical bottom line

Optimizing vaccination uptake and effectiveness in older adults beyond COVID-19 remains a critical public health priority given their increased vulnerability to infectious diseases such as influenza, pneumococcal disease, and herpes zoster. Evidence highlights multifactorial barriers to vaccine acceptance, including hesitancy driven by misinformation and access issues, as well as immunosenescence that may reduce vaccine immunogenicity. Tailored strategies combining patient education, healthcare provider engagement, and system-level interventions can improve uptake. Additionally, emerging evidence supports the use of enhanced vaccine formulations and booster doses to augment immune responses in this population. However, ongoing surveillance and individualized approaches are needed to balance benefits and risks, especially in frail or multimorbid older adults.

What the evidence shows

Older adults face distinct challenges regarding vaccination, including biological factors such as immunosenescence that impair vaccine-induced immunity and psychosocial factors contributing to vaccine hesitancy. McSpadden et al. (2021) emphasize that vaccine hesitancy in older adults is influenced by concerns about vaccine safety, perceived low risk of disease, and mistrust in healthcare systems, which may extend beyond COVID-19 vaccines to other recommended immunizations. Weinberger et al. (2021) provide a comprehensive overview of vaccines routinely recommended for older adults—namely influenza, pneumococcal, and herpes zoster vaccines—and discuss how immunosenescence reduces vaccine effectiveness, necessitating strategies such as high-dose or adjuvanted vaccines to improve protection.

Cost-effectiveness analyses, as reviewed in the literature, support vaccination strategies targeting herpes zoster and influenza in older adults, demonstrating reductions in disease burden and healthcare costs. Gong et al. (2024) further highlight lessons from COVID-19 vaccination campaigns, showing that booster doses can enhance protection against emerging infectious and virulent strains in older populations, suggesting a potential model for other vaccines. Broccolo et al. (2022) discuss the role of laboratory stewardship in optimizing vaccine effectiveness, including monitoring immune responses to guide booster timing.

Despite these advances, Armstrong et al. (2023) report rare but notable adverse events such as delirium following COVID-19 vaccination in older adults, underscoring the need for vigilance and individualized risk assessment. Moreau et al. (2024) caution that vaccination can occasionally cause misleading findings in oncologic imaging, an important consideration in older adults with cancer histories.

Caveats and uncertainty

The heterogeneity of the older adult population complicates generalizations about vaccine efficacy and safety. Immunosenescence varies widely with age, comorbidities, and frailty, and data on vaccine effectiveness in the oldest old or those with significant multimorbidity remain limited. Vaccine hesitancy drivers are complex and context-dependent, with cultural, socioeconomic, and health literacy factors influencing uptake differently across populations. While enhanced vaccine formulations show promise, long-term safety and comparative effectiveness data are still evolving.

The COVID-19 pandemic has accelerated vaccine research and deployment but also introduced unique challenges, such as misinformation and rapidly changing recommendations, which may not fully extrapolate to other vaccines. Additionally, the optimal timing and frequency of booster doses for vaccines beyond COVID-19 are not yet well defined. Rare adverse events, although uncommon, require ongoing pharmacovigilance, especially in frail older adults.

How this may change practice

Clinicians should adopt a proactive, patient-centered approach to vaccination in older adults, addressing hesitancy through clear communication about vaccine benefits and risks tailored to individual concerns. Utilizing enhanced vaccine formulations (e.g., high-dose influenza vaccines) and considering booster doses where evidence supports improved immunity can optimize protection. Coordination with multidisciplinary teams and leveraging electronic health records to identify vaccination gaps can improve coverage.

Laboratory monitoring of immune responses may become a valuable tool to personalize vaccination schedules, although this approach requires further validation. Awareness of potential vaccine-related adverse events, including neurocognitive effects and imaging artifacts, is important for clinical decision-making and patient counseling.

Ultimately, integrating vaccination strategies into comprehensive geriatric care plans that consider frailty, comorbidities, and patient preferences will be essential to maximize benefits and minimize harms. Continued research and surveillance will inform evolving guidelines and best practices.


References

  1. McSpadden J, et al. Vaccine Hesitancy among Older Adults, with Implications for COVID-19 Vaccination and Beyond. 2021 DOI:10.26419/ppi.00123.001
  2. Weinberger B, et al. Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing 2021;18:12. DOI:10.1186/s12979-021-00249-6
  3. Gong Y, et al. The Effectiveness Of COVID-19 Vaccination in Protecting Older Adults Against Emerging Infectious and Virulent Strains. Highlights Sci Eng Technol 2024. DOI:10.54097/9qxcpk04
  4. Broccolo F, et al. Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role? Clin Chem Lab Med 2022;60:1234-1242. DOI:10.1515/cclm-2021-1345
  5. Armstrong K, et al. Delirium after COVID-19 vaccination in older adults. Nursing 2023;53:18-20. DOI:10.1097/01.nurse.0000927432.51378.e7
  6. Moreau A, et al. Misleading FDG Uptake in Oncology Assessment. Clin Nucl Med 2024;49:45-50. DOI:10.1097/rlu.0000000000005049

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team